脊髓损伤后继发的神经元细胞凋亡、脱髓鞘和胶质瘢痕增生，是限制损伤后神经修复的重要原因。我们前期研究显示，生长因子bFGF在脊髓损伤后早期具有减少神经元细胞凋亡、保护血脊髓屏障等作用；低剂量的微管稳定剂多西他赛（DTX）在具有抑制胶质瘢痕和促进轴突生长神经再生作用；两者联合应用具有明显的协同修复效果。但由于bFGF/DTX间理化性质差异大，体内分布缺乏特异性，目前仍缺乏有效方法高效联合用药。本项目拟构建可注射型的硫酸软骨素（CSPGs）靶向脂质体丝素凝胶共同包载bFGF/DTX，原位注射形成三维支撑型凝胶，通过多种技术手段综合评价其协同修复效果，观察原位注射CSPGs亲和性脂质体丝素凝胶对于脊髓损伤模型动物的神经修复效果，阐释其作用机制。本项目将靶向制剂新技术、多重药物治疗、生物材料多学科技术融合，克服已有治疗方法的局限，旨在探索脊髓损伤后神经再生修复的理想策略。

Several secondary cascades after spinal cord injury, including apoptosis of neuron cells, demyelination, and over growth of glial scar, were considered to be the main cause of inhibition of neural regeneration. In our previous study, bFGF inhibited cell apoptosis and protected the blood spinal cord barrier after spinal injury; low dose of docetaxel was able to inhibit formation of glial scar and induce axon regeneration; which of those combination shown obvious synergistic reaction. However, in view of the inconsistent pharmacokinetics profiles between the concomitant drug (bFGF/DTX) with different physiochemical characteristics and non-specific distribution, there are few strategies with high efficiency to deliver them in treatment. In this project, we firstly design a new CSPGs-targeted liposome (CSPGs-Lip) in the silk fibroin (SF) hydrogel to encapsulate simultaneously bFGF and DTX. Combine with in situ injection to form a three-dimensional supporting gel, investigate the effect and mechanism of CSPGs-Lip-SF hydrogel with multiple comprehensive evaluation system in spinal cord injury models. This strategy will combine "targeted delivery system", "combinational therapy of multiple drug", "biomaterials", to overcome the limitation of existing therapies, and aim to develop satisfied strategy for neural regeneration after spinal cord injury.